Transdiagnostic efficacy of lurasidone on depressive symptoms: systematic review and meta-analysis of randomised controlled trials
Lurasidone is a potentially efficacious and safe strategy for reducing depressive symptomatology across a range of psychiatric diagnoses. Further long-term, robust trials employing precision psychiatry methods are needed to support its broader use to target depressive symptoms transdiagnostically.
Authors
- Andrea Fiorillo (ORCID: https://orcid.org/0000-0002-6926-0762)
- Ana Ghenciulescu (ORCID: https://orcid.org/0000-0001-5583-8300)
- Gaia Sampogna (ORCID: https://orcid.org/0000-0002-9547-2793)
- Riccardo De Giorgi (ORCID: https://orcid.org/0000-0001-5984-8696)
- Amedeo Minichino (ORCID: https://orcid.org/0000-0002-6309-6324)
- Anna Pearse
Institutions
- University of Campania "Luigi Vanvitelli" (IT)
- University Hospitals of North Midlands NHS Trust (GB)
- Oxford Health NHS Foundation Trust (GB)
- John Radcliffe Hospital (GB)
- Warneford Hospital (GB)
- University of Oxford (GB)
Publication Details
- Journal
- The British Journal of Psychiatry
- Published
- 2025-08-20
- DOI
- https://doi.org/10.1192/bjp.2025.10343
- Citations
- 2
- Primary Topic
- Bipolar Disorder and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 2.94